Joe Jimenez, Novartis CEO, discusses how the move in the Swiss franc impacted his company, innovative drugs in the pipeline, and pharmaceutical pricing issues.» Read More
Bristol Myers offered a cool $4.5 billion for ImClone Thursday. Is now the time to play biotech?
In the last month healthcare has emerged as the best performing sector in the S&P. Are drug makers a cure for your portfolio in this economic downturn?
Roche Holdings' $43.7 billion bid to buy the rest of Genentech highlights drugmakers' growing reliance on biotech products.
Swiss drugmaker Roche Holding offered to acquire all outstanding shares in its U.S. partner Genentech for $43.7 billion in cash to reinforce its position in cancer medicines.
In Thursday’s Web Extra the traders talk China – now growing at its slowest pace since 2005. Also Pete Najarian has more fun with Pharma.
Second-quarter net profit at Novartis rose 17 percent to $2.27 billion, helped by the weak U.S. dollar and cost cutting efforts, beating forecasts and boosting its shares.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The S&P closed 20% below its all-time high set in October, making it the last of the three major U.S. stock indexes to fall into a bear market. What's the "Word on the Street?"
In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.
What are the best plays when the market enters bear territory?
Paul Larson says it's time to get back into equities. The equities strategist at Morningstar says buying stocks now will set up your portfolio for a big payoff in three to five years. Larson offered CNBC his top U.S. stocks.
It was an ugly first half for the stock market and now that the goal posts have been moved for the economic recovery, expect a rough game in the second half.
Here's how you can play healthcare with either a McCain or Obama presidency!
Following are the day’s biggest winners and losers. Find out why shares of Raytheon and Pulte popped while UPS and Cooper Tire dropped.
The Dow closed lower on Tuesday with stocks slipping on concerns about the economy after consumer confidence fell to a 16-year low. What's the "Word on the Street?"
Despite at least a couple of analysts coming out with relatively bullish post-ASCO research notes on Pfizer's oncology drug pipeline, PFE shares have fallen to yet another new low intra-day and have crossed another threshold.
A bout of risk aversion dented European stocks on Tuesday as jitters grew over potential credit-related problems at banks and inflation, while typically defensive stocks such as pharmaceuticals and food rallied.
This is gonna be a crazy couple of days. At 9 pm ET tonight the American Society of Clinical Oncology is putting nearly 5,000 studies on its website all at once. Although ASCO says it's all about the science and protecting the "scientific integrity" of its upcoming conference, this is, frankly, an attempt to level the playing field for Wall Street.
Mars confirmed that it is buying Wrigley's for $23B in partnership with Warren Buffett. The deal would rank as the third biggest deal of the year. Here are the top deals of year to date...
The Dow pulled back Monday after a weaker-than-expected profit report from Bank of America stirred concerns about the health of corporate earnings. What's the "Word on The Street?"